These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24762578)

  • 1. Age-related macular degeneration: vision challenge of old age.
    Wang F; Sun X
    Chin Med J (Engl); 2014; 127(8):1405-6. PubMed ID: 24762578
    [No Abstract]   [Full Text] [Related]  

  • 2. Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity.
    Jonas JB; Tao Y; Rensch F
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):401-5. PubMed ID: 21810019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiangiogenic agents in ARMD treatment].
    Coroi MC; Demea S; Todor M; Apopei E
    Oftalmologia; 2012; 56(1):51-7. PubMed ID: 22888687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of age-related macular degeneration treatment trials: what did we learn?
    Csaky KG
    Retina; 2012 Mar; 32(3):413-6. PubMed ID: 22374153
    [No Abstract]   [Full Text] [Related]  

  • 5. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
    Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
    BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B; Adewoyin T; Patel SK; Sivaprasad S
    Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bevacizumab versus ranibizumab: a draw?].
    Souied EH; Cohen SY; Kodjikian L
    J Fr Ophtalmol; 2012 Feb; 35(2):79-81. PubMed ID: 22033297
    [No Abstract]   [Full Text] [Related]  

  • 8. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration.
    Unver YB; Yavuz GA; Bekiroğlu N; Presti P; Li W; Sinclair SH
    Eye (Lond); 2009 Feb; 23(2):453-60. PubMed ID: 19039333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F
    Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice.
    Jonas JB; Tao Y; Schlichtenbrede FC
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):467-70. PubMed ID: 21682590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal therapy in bilateral neovascular age-related macular degeneration.
    Barthelmes D; Walton RJ; Arnold JJ; McAllister IL; Simpson JM; Campain A; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC;
    Ophthalmology; 2014 Oct; 121(10):2073-4. PubMed ID: 24939512
    [No Abstract]   [Full Text] [Related]  

  • 13. Charles Bonnet syndrome improves when treatment is effective in age-related macular degeneration.
    Singh A; Sørensen TL
    Br J Ophthalmol; 2011 Feb; 95(2):291-2. PubMed ID: 20733019
    [No Abstract]   [Full Text] [Related]  

  • 14. Intersession repeatability of visual acuity scores in age-related macular degeneration.
    Patel PJ; Chen FK; Rubin GS; Tufail A
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4347-52. PubMed ID: 18566455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
    Pushpoth S; Sykakis E; Merchant K; Browning AC; Gupta R; Talks SJ
    Br J Ophthalmol; 2012 Dec; 96(12):1469-73. PubMed ID: 23001255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing treatments for age-related macular degeneration: safety, effectiveness and cost.
    Maguire MG
    LDI Issue Brief; 2012 Jun; 17(8):1-4. PubMed ID: 22754971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How significant is the benefit that a patient can expect from a VEGF inhibitor?
    Johns Hopkins Med Lett Health After 50; 2012; 24(12):4. PubMed ID: 23757794
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
    El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
    Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avastin and Lucentis are equally effective in treating AMD.
    Optom Vis Sci; 2011 Jul; 88(7):E895-6. PubMed ID: 21709531
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
    Jonas JB; Tao Y; Rensch F
    Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.